Vimarsana
Biggest News Aggregation in the World

Samuil Umansky News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Samuil Umansky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Samuil Umansky Today - Breaking & Trending Today

CRDF Stock Price | Cardiff Oncology Inc. Stock Quote (U.S.: Nasdaq) - Vimarsana News

CRDF Stock Price | Cardiff Oncology Inc. Stock Quote (U.S.: Nasdaq)

CRDF | Complete Cardiff Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

DiamiR Biosciences Announces Publication of Analytical Validation Data for its microRNA Testing Platform - Vimarsana News

DiamiR Biosciences Announces Publication of Analytical Validation Data for its microRNA Testing Platform

/PRNewswire/ -- DiamiR Biosciences, a developer of innovative non-invasive blood-based diagnostic tests for brain health and other diseases, today announced...

Head-To-Head Contrast: Cardiff Oncology (NASDAQ:CRDF) & Dyadic International (NASDAQ:DYAI) - Vimarsana News

Head-To-Head Contrast: Cardiff Oncology (NASDAQ:CRDF) & Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Valuation and Earnings This table compares Dyadic International and […]

Head to Head Analysis: Autolus Therapeutics (NASDAQ:AUTL) and Cardiff Oncology (NASDAQ:CRDF) - Vimarsana News

Head to Head Analysis: Autolus Therapeutics (NASDAQ:AUTL) and Cardiff Oncology (NASDAQ:CRDF)

Cardiff Oncology (NASDAQ:CRDF – Get Rating) and Autolus Therapeutics (NASDAQ:AUTL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Risk & Volatility Cardiff Oncology has a beta of […]

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences - Vimarsana News

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences

DiamiR Announces Acquisition of CLIA Lab from Interpace Biosciences News provided by Share this article Share this article MONMOUTH JUNCTION, N.J., March 17, 2021 /PRNewswire/ -- DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has entered into a definitive agreement to acquire a CLIA (Clinical Laboratory Improvement Amendments) certified laboratory in New Haven, CT from Interpace Biosciences, Inc. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by ...